Saturday, 17 May 2014 11:43

Anticoagulation news items. Week commencing 12th May 2014

Simvastatin in aneurysmal subarachnoid haemorrhage (STASH): a multicentre randomised phase 3 trial

The Lancet Neurology
No benefit was seen in the use of simvastatin (40mg daily for upto 21 days) for long-term or short-term outcome in patients with aneurysmal subarachnoid haemorrhage (n=803). It is concluded these patients should not be treated routinely with simvastatin during acute stages.


Is there more to learn about cytochrome P450 enzymes?

Drug and Therapeutics Bulletin
This article provides a brief overview of cytochrome P450 (CYP) enzyme classification, drug interactions, P-glycoprotein and CYP3A4, pharmacogenomics and CYP P450; and alteration of CYP P450 activity by disease.


Pradaxa (dabigatran): Drug Safety Communication - Lower Risk for Stroke and Death, but Higher Risk for GI Bleeding Compared to Warfarin

US Food and Drug Administration
Results of an observational cohort study carried out by the FDA as part of its ongoing review of dabigatran have shown it to be associated with a lower risk of ischaemic stroke, ICH and death, and increased risk of major GI bleeding and a similar risk of MI compared to warfarin.


Revised SPC: Eliquis (apixaban) 2.5mg and 5mg film-coated tablets

electronic Medicines Compendium
A statement that patients can stay on apixaban while being cardioverted has been added to section 4.2 (Posology and method of administration).



The above records have been identified by UKMi and feature in the NICE Medicines Awareness Service. Further details on this service can be found at: